95 related articles for article (PubMed ID: 23229283)
1. miRNA expression profile in human osteosarcoma: role of miR-1 and miR-133b in proliferation and cell cycle control.
Novello C; Pazzaglia L; Cingolani C; Conti A; Quattrini I; Manara MC; Tognon M; Picci P; Benassi MS
Int J Oncol; 2013 Feb; 42(2):667-75. PubMed ID: 23229283
[TBL] [Abstract][Full Text] [Related]
2. Analysis of a Preliminary microRNA Expression Signature in a Human Telangiectatic Osteogenic Sarcoma Cancer Cell Line.
Palmini G; Romagnoli C; Donati S; Zonefrati R; Galli G; Marini F; Iantomasi T; Aldinucci A; Leoncini G; Franchi A; Beltrami G; Campanacci DA; Capanna R; Brandi ML
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503899
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA Expression Changes and Integrated Pathways Associated With Poor Outcome in Canine Osteosarcoma.
Dailey DD; Hess AM; Bouma GJ; Duval DL
Front Vet Sci; 2021; 8():637622. PubMed ID: 33937369
[TBL] [Abstract][Full Text] [Related]
4. Molecular Subtyping and Survival Analysis of Osteosarcoma Reveals Prognostic Biomarkers and Key Canonical Pathways.
Southekal S; Shakyawar SK; Bajpai P; Elkholy A; Manne U; Mishra NK; Guda C
Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046795
[TBL] [Abstract][Full Text] [Related]
5. MiR-133b is down-regulated in human osteosarcoma and inhibits osteosarcoma cells proliferation, migration and invasion, and promotes apoptosis.
Zhao H; Li M; Li L; Yang X; Lan G; Zhang Y
PLoS One; 2013; 8(12):e83571. PubMed ID: 24391788
[TBL] [Abstract][Full Text] [Related]
6. miRNA-646 suppresses osteosarcoma cell metastasis by downregulating fibroblast growth factor 2 (FGF2).
Sun XH; Geng XL; Zhang J; Zhang C
Tumour Biol; 2015 Mar; 36(3):2127-34. PubMed ID: 25403884
[TBL] [Abstract][Full Text] [Related]
7. miR-214 promotes the proliferation and invasion of osteosarcoma cells through direct suppression of LZTS1.
Xu Z; Wang T
Biochem Biophys Res Commun; 2014 Jun; 449(2):190-5. PubMed ID: 24802407
[TBL] [Abstract][Full Text] [Related]
8. MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway.
Li J; You T; Jing J
Cell Prolif; 2014 Apr; 47(2):152-60. PubMed ID: 24517182
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-199b-5p is involved in the Notch signaling pathway in osteosarcoma.
Won KY; Kim YW; Kim HS; Lee SK; Jung WW; Park YK
Hum Pathol; 2013 Aug; 44(8):1648-55. PubMed ID: 23574781
[TBL] [Abstract][Full Text] [Related]
10. Non-coding RNAs as potential therapeutic targets for receptor tyrosine kinase signaling in solid tumors: current status and future directions.
Moeinafshar A; Nouri M; Shokrollahi N; Masrour M; Behnam A; Tehrani Fateh S; Sadeghi H; Miryounesi M; Ghasemi MR
Cancer Cell Int; 2024 Jan; 24(1):26. PubMed ID: 38200584
[TBL] [Abstract][Full Text] [Related]
11. Canine osteosarcoma in comparative oncology: Molecular mechanisms through to treatment discovery.
Simpson S; Rizvanov AA; Jeyapalan JN; de Brot S; Rutland CS
Front Vet Sci; 2022; 9():965391. PubMed ID: 36570509
[TBL] [Abstract][Full Text] [Related]
12. Analysis of circRNA and miRNA expression profiles in IGF3-induced ovarian maturation in spotted scat (
Li Z; Guo Y; Ndandala CB; Chen H; Huang C; Zhao G; Huang H; Li G; Chen H
Front Endocrinol (Lausanne); 2022; 13():998207. PubMed ID: 36506051
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic Dysregulation of Circulating Noncoding RNAs: Novel Challenges and Opportunities in Sarcoma Diagnosis and Treatment.
Chellini L; Palombo R; Riccioni V; Paronetto MP
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230599
[TBL] [Abstract][Full Text] [Related]
14. A Novel Risk-Score Model With Eight MiRNA Signatures for Overall Survival of Patients With Lung Adenocarcinoma.
Wu J; Lou Y; Ma YM; Xu J; Shi T
Front Genet; 2021; 12():741112. PubMed ID: 34868213
[TBL] [Abstract][Full Text] [Related]
15. The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors.
Geisler L; Mohr R; Lambrecht J; Knorr J; Jann H; Loosen SH; Özdirik B; Luedde T; Hammerich L; Tacke F; Wree A; Hellberg T; Roderburg C
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445276
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomic Effects of β-Blocker Use on Femoral Neck Bone Mineral Density.
Nevola KT; Nagarajan A; Hinton AC; Trajanoska K; Formosa MM; Xuereb-Anastasi A; van der Velde N; Stricker BH; Rivadeneira F; Fuggle NR; Westbury LD; Dennison EM; Cooper C; Kiel DP; Motyl KJ; Lary CW
J Endocr Soc; 2021 Aug; 5(8):bvab092. PubMed ID: 34195528
[TBL] [Abstract][Full Text] [Related]
17. MicroRNAs as Biomarkers in Canine Osteosarcoma: A New Future?
Gourbault O; Llobat L
Vet Sci; 2020 Sep; 7(4):. PubMed ID: 33008041
[TBL] [Abstract][Full Text] [Related]
18. microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1α/HES1 signaling axis.
Yang D; Xu T; Fan L; Liu K; Li G
J Exp Clin Cancer Res; 2020 Sep; 39(1):201. PubMed ID: 32972441
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs signatures, bioinformatics analysis of miRNAs, miRNA mimics and antagonists, and miRNA therapeutics in osteosarcoma.
Otoukesh B; Abbasi M; Gorgani HO; Farahini H; Moghtadaei M; Boddouhi B; Kaghazian P; Hosseinzadeh S; Alaee A
Cancer Cell Int; 2020; 20():254. PubMed ID: 32565738
[TBL] [Abstract][Full Text] [Related]
20. miR-106B-25 Cluster expression: a comparative human and canine osteosarcoma study.
Leonardi L; Benassi MS; Pollino S; Locaputo C; Pazzaglia L
Vet Rec Open; 2020; 7(1):e000379. PubMed ID: 32201579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
